Product Images Mayzent
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 7 images provide visual information about the product associated with Mayzent NDC 0078-1014 by Novartis Pharmaceuticals Corporation, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
siponimod structural formula - baf312 01
Figure 1 Time to Confirmed Disability Progression Based on EDSS (Study 1) - baf312 02
This appears to be a graph or chart comparing results of a study between a drug called "Mayzent" and a placebo. The study involved 1,099 patients taking Mayzent and 546 taking a placebo. The graph shows the percentage of patients with confirmed EDSS progression over a period of time (12, 24, and 30 months). The study found that Mayzent showed a 21% reduction in relative risk compared to placebo, with a p-value of 0.013 and 95% confidence interval of 0.65 to 0.95.*
Figure 2 Time to Confirmed Disability Progression Based on EDSS (Study 1), Subgroup Analysis - baf312 03
Novartis logo - baf312 04
PRINCIPAL DISPLAY PANEL NDC 0078-0986-15 Rx only MAYZENT® (siponimod) tablets 2 mg 30 tablets Dispense with accompanying Medication Guide. NOVARTIS - baf312 05
PRINCIPAL DISPLAY PANEL NDC 0078-0979-50 Rx only MAYZENT® (siponimod) tablets 0.25 mg 28 tablets Dispense with accompanying Medication Guide. NOVARTIS - baf312 06
baf312 07
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.